Verona Pharma (VRNA)
(Delayed Data from NSDQ)
$29.60 USD
-0.39 (-1.30%)
Updated Sep 23, 2024 04:00 PM ET
After-Market: $29.58 -0.02 (-0.07%) 7:58 PM ET
5-Strong Sell of 5 5
F Value F Growth B Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
VRNA 29.60 -0.39(-1.30%)
Will VRNA be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for VRNA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VRNA
Verona (VRNA) Stock Surges 36% in the Past Month: Here's Why
FDA Delays Decision on Sanofi (SNY)-Regeneron Dupixent in COPD
VRNA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Ligand (LGND) Q4 Earnings Surpass Estimates, Stock Surges
Fluor Corporation and Align Technology have been highlighted as Zacks Bull and Bear of the Day
3 Beaten-Down Biotech Stocks to Buy for a Turnaround in 2024
Other News for VRNA
Buy Rating Affirmed for Verona Pharma Amid Strategic Partnership and Market Potential for Novel COPD Treatment
Ritedose is Proud to Partner with Verona Pharma to Deliver First-In-Class COPD Drug, Ohtuvayre (ensifentrine)*
Verona Pharma partners with Ritedose to deliver Ohtuvayre drug for COPD
Verona Pharma's Ohtuvayre Set To Unlock Significant Value In COPD Care
Insider Sale: CFO Mark Hahn Sells 600,000 Shares of Verona Pharma PLC (VRNA)